Search

Search Constraints

You searched for: Author/Creator Gray, Kathryn P.

Search Results

1. A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration‐resistant prostate cancer. Issue 14 (7th June 2018)

2. Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer. Issue 15 (22nd April 2015)

3. Elevated IL‐8, TNF‐α, and MCP‐1 in men with metastatic prostate cancer starting androgen‐deprivation therapy (ADT) are associated with shorter time to castration‐resistance and overall survival. Issue 8 (26th March 2014)

4. Elevated insulin‐like growth factor binding protein‐1 (IGFBP‐1) in men with metastatic prostate cancer starting androgen deprivation therapy (ADT) is associated with shorter time to castration resistance and overall survival. Issue 3 (16th October 2013)

5. Pharmacokinetics, Tolerability, and Safety of Doravirine and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination Tablets in Adolescents Living With HIV: Week 24 Results From IMPAACT 2014. (1st February 2023)

6. Risk of prostate cancer‐specific death in men with baseline metabolic aberrations treated with androgen deprivation therapy for biochemical recurrence. (8th March 2016)

7. Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC). Issue 12 (29th April 2018)